Areclok (bicalutamidum) coated tablets 50 mg. №30

$220.70

Manufacturer: Latvia

Areclok is a non-steroidal anti-androgen drug without other endocrine activity. Binding to androgen receptors without activating gene expression suppresses androgenic stimuli. The result of this suppression is the regression of prostate tumors. Discontinuation of bicalutamide treatment may lead to antiandrogen withdrawal syndrome in some patients.

Category:

Description

Ingredients:

active substance: bicalutamidum;

1 tablet contains bicalutamide 50 mg;

excipients: lactose monohydrate; povidone K-30; sodium starch glycolate (type A); magnesium stearate;

shell: Opadray white Y-1-7000 (hypromellose titanium dioxide (E 171) macrogol 400).

Main physico-chemical properties: white round biconvex tablets covered with a film shell.

Antagonists of hormones and similar means. Antiandrogens.

ATX code L02B B03.

Pharmacological properties.

Pharmacodynamics.

Areclok (bicalutamidum) is a non-steroidal anti-androgen drug without other endocrine activity. Binding to androgen receptors without activating gene expression suppresses androgenic stimuli. The result of this suppression is the regression of prostate tumors. Discontinuation of bicalutamide treatment may lead to antiandrogen withdrawal syndrome in some patients.

Bicalutamide is characterized by a low degree of affinity for GHSH (sex hormone-binding globulin), but this has no clinical significance.

Areclok (bicalutamidum) contains a racemic mixture characterized by antiandrogenic activity mainly due to the (R)-enantiomer.

Indication.

Prostate cancer (advanced stages) in combination with therapy with luteinizing hormone-releasing factor analogues or surgical castration.

Contraindication.

Bicalutamide is contraindicated for women and children.

Simultaneous use of Areclok (bicalutamidum) with terfenadine, astemizole or cisapride is contraindicated.

Dosage and Administration.

Adult male patients, including elderly patients : 1 tablet once a day. Treatment with bicalutamide should be started at least 3 days before starting therapy with luteinizing hormone-releasing factor analogues or simultaneously with surgical castration.

With renal insufficiency: no individual dose adjustment is required.

With hepatic insufficiency: no individual dose adjustment is required for patients with moderate hepatic insufficiency. Accumulation of bicalutamide may occur in patients with moderate or severe hepatic impairment.